SEC Comment Letter 0000000000-25-000589 to Metsera, Inc. (MTSR) (CIK 0002040807)
Metsera, Inc. (MTSR) (CIK 0002040807)
Date: Jan. 21, 2025 · CIK: 0002040807 · Accession: 0000000000-25-000589
AI Filing Summary & Sentiment
File numbers found in text: 333-284225
Referenced dates: November 22, 2024
Letter
January 21, 2025 Christopher Whitten Bernard Chief Executive Officer Metsera, Inc. 3 World Trade Center 175 Greenwich Street New York, New York 10007 Re:Metsera, Inc. Registration Statement on Form S-1 Filed January 10, 2025 File No. 333-284225 Dear Christopher Whitten Bernard: We have reviewed your registration statement and have the following comment. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe a comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to this letter, we may have additional comments. Registration Statement on Form S-1 filed January 10, 2025 Use of Proceeds, page 91 1.We note your revised Use of Proceeds disclosure and reissue prior comment 18 from our letter dated November 22, 2024. Please further revise your Use of Proceeds section to state how far in the development process you estimate the proceeds from this offering will enable you to reach for both your MET-233i and MET-244o product candidates. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate
January 21, 2025 Page 2 time for us to review any amendment prior to the requested effective date of the registration statement. Please contact Tracie Mariner at 202-551-3744 or Lynn Dicker at 202-551-3616 if you have questions regarding comments on the financial statements and related matters. Please contact Jason Drory at 202-551-8342 or Chris Edwards at 202-551-6761 with any other questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:B. Shayne Kennedy
Show Raw Text
January 21, 2025
Christopher Whitten Bernard
Chief Executive Officer
Metsera, Inc.
3 World Trade Center
175 Greenwich Street
New York, New York 10007
Re:Metsera, Inc.
Registration Statement on Form S-1
Filed January 10, 2025
File No. 333-284225
Dear Christopher Whitten Bernard:
We have reviewed your registration statement and have the following comment.
Please respond to this letter by amending your registration statement and providing
the requested information. If you do not believe a comment applies to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
After reviewing any amendment to your registration statement and the information
you provide in response to this letter, we may have additional comments.
Registration Statement on Form S-1 filed January 10, 2025
Use of Proceeds, page 91
1.We note your revised Use of Proceeds disclosure and reissue prior comment 18 from
our letter dated November 22, 2024. Please further revise your Use of Proceeds
section to state how far in the development process you estimate the proceeds from
this offering will enable you to reach for both your MET-233i and MET-244o product
candidates.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence
of action by the staff.
Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate
January 21, 2025
Page 2
time for us to review any amendment prior to the requested effective date of the registration
statement.
Please contact Tracie Mariner at 202-551-3744 or Lynn Dicker at 202-551-3616 if
you have questions regarding comments on the financial statements and related
matters. Please contact Jason Drory at 202-551-8342 or Chris Edwards at 202-551-6761 with
any other questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:B. Shayne Kennedy